EPS miss of 75% vs consensus will pressure the stock near-term. Monitor analyst reactions and any cost control initiatives. The DAYBUE growth and guidance reaffirmation provide a floor, but rising SG&A is a concern.
ACAD drugs
ACAD drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $22.56entry
- T+1 · 6mo ago 0.00%α −0.83% · $22.56
- T+5 · 6mo ago −1.68%α −3.19% · $22.18
- T+20 · 6mo ago −5.01%α −8.14% · $21.43
- T+60 · 4mo ago +13.52%α +9.69% · $25.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (vs $280.3M est). Revenue grew 10% YoY, but EPS fell 82% YoY due to a 36% surge in SG&A expenses. Full-year 2026 guidance was reaffirmed, providing some stability.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP revenue $268M, up 10% YoY from $244M
- Q1 2026 GAAP diluted EPS $0.02, down 82% from $0.11 YoY
- SG&A expense $171M, up 36% from $126M YoY, driving operating loss
- DAYBUE net sales $101M (+20% YoY), NUPLAZID $167M (+5% GAAP, +6% adjusted)
- Full-year 2026 guidance reaffirmed: revenue $1.22-1.28B
Financial Impact
EPS miss of 75% vs consensus ($0.02 actual vs $0.08 est); revenue miss of ~4%
Risk Factors
- Continued SG&A cost inflation without corresponding revenue acceleration
- Remlifanserin Phase 2 data risk (readout Aug-Oct 2026)
- IRA rebate adjustments may cause further earnings volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-209253 |
| Document: acad-20260506.htm | 0001193125-26-209253 |
| Document: 0001193125-26-209253-index-headers.html | 0001193125-26-209253 |
| Document: 0001193125-26-209253-index.html | 0001193125-26-209253 |
| Document: 0001193125-26-209253.txt | 0001193125-26-209253 |
| 8-K Data (Synthetic) | 0001193125-26-209253 |
Track record
14 reports on ACAD
0 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +1.40% at T+1 after the Jun 11, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $18.28 Now $18.67 +2.13% settles Dec 9
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $21.24 Now $18.67 −12.10% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
- Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
- Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Viewing Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers